These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1506 related articles for article (PubMed ID: 32714324)

  • 21. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Qa-1
    Zhang X; Sabio E; Krishna C; Ma X; Wang J; Jiang H; Havel JJ; Chan TA
    Mol Cancer Res; 2021 Jun; 19(6):1076-1084. PubMed ID: 33674442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.
    Archilla-Ortega A; Domuro C; Martin-Liberal J; Muñoz P
    J Exp Clin Cancer Res; 2022 Feb; 41(1):62. PubMed ID: 35164813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human NK cells: From surface receptors to clinical applications.
    Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
    Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
    Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
    Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selenium-Containing Nanocomplexes Achieve Dual Immune Checkpoint Blockade for NK Cell Reinvigoration.
    Xianyu B; Pan S; Gao S; Xu H; Li T
    Small; 2024 May; 20(19):e2306225. PubMed ID: 38072799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy.
    Beelen NA; Valckx VTC; Bos GMJ; Wieten L
    Best Pract Res Clin Haematol; 2024 Sep; 37(3):101568. PubMed ID: 39396258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploiting Human NK Cells in Tumor Therapy.
    Vacca P; Pietra G; Tumino N; Munari E; Mingari MC; Moretta L
    Front Immunol; 2019; 10():3013. PubMed ID: 32010130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer.
    Li G; Liu X; Gu C; Ma G; Li S; Ma Z; Xiong Y; Jiang Y; Huang Q; Wu J; Wu Z; Liao W; Wu Q; Shi M
    J Transl Med; 2024 Aug; 22(1):718. PubMed ID: 39097734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer.
    Sivori S; Della Chiesa M; Carlomagno S; Quatrini L; Munari E; Vacca P; Tumino N; Mariotti FR; Mingari MC; Pende D; Moretta L
    Front Immunol; 2020; 11():2156. PubMed ID: 33013909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.
    Mariotti FR; Quatrini L; Munari E; Vacca P; Moretta L
    Front Immunol; 2019; 10():910. PubMed ID: 31105707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
    Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
    JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
    Smits NC; Coupet TA; Godbersen C; Sentman CL
    Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy.
    Devillier R; Chrétien AS; Pagliardini T; Salem N; Blaise D; Olive D
    J Leukoc Biol; 2021 Jun; 109(6):1071-1088. PubMed ID: 32991746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence.
    Ahmetlic F; Fauser J; Riedel T; Bauer V; Flessner C; Hömberg N; Hennel R; Brenner E; Lauber K; Röcken M; Mocikat R
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33441389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
    André P; Denis C; Soulas C; Bourbon-Caillet C; Lopez J; Arnoux T; Bléry M; Bonnafous C; Gauthier L; Morel A; Rossi B; Remark R; Breso V; Bonnet E; Habif G; Guia S; Lalanne AI; Hoffmann C; Lantz O; Fayette J; Boyer-Chammard A; Zerbib R; Dodion P; Ghadially H; Jure-Kunkel M; Morel Y; Herbst R; Narni-Mancinelli E; Cohen RB; Vivier E
    Cell; 2018 Dec; 175(7):1731-1743.e13. PubMed ID: 30503213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.